Literature DB >> 32109457

Combined effects of berberine and evodiamine on colorectal cancer cells and cardiomyocytes in vitro.

Xiaoyong Guan1, Xiaoting Zheng2, Chi Teng Vong2, Jinyao Zhao3, Jianbo Xiao2, Yitao Wang4, Zhangfeng Zhong5.   

Abstract

Chemotherapy induces inevitable adverse effects, while complementary and alternative medicine employs many chemical substances. Herb pairs normally contain two herbal medicines, and they have satisfactory effects on cancer therapy. Zuojinwan, a well-known herb pair, is composed of Coptidis Rhizoma and Euodiae Fructus. Berberine and evodiamine are considered the most important compounds in the Zuojinwan herb pair. Previous reports have shown that combined use of evodiamine and berberine displays synergistic anticancer activities in various types of cancers, but this combination has not been tested in colorectal cancer. Hence, this study aimed to explore the combined effects of evodiamine and berberine on colorectal cancer cell lines and cardiomyocytes. We found that the combination of berberine and evodiamine showed synergistic anticancer activity in P-glycoprotein (P-gp)-positive colorectal cancer cells through attenuating the overexpression of P-gp mRNA independent of cell cycle arrest and cell apoptosis. However, berberine did not increase the cytotoxicity of evodiamine in normal human colon mucosal epithelial cells. Furthermore, berberine attenuated evodiamine-induced cardiotoxicity by regulating extrinsic apoptosis via nuclear factor erythroid-2-related factor 2 (Nrf2)-dependent and reactive oxygen species-independent pathways. Therefore, we suggest that the combination of berberine and evodiamine displays high anticancer activity while reducing the side effects in specific cell lines.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Berberine; Cardiomyocyte; Colorectal cancer; Evodiamine; Synergism

Mesh:

Substances:

Year:  2020        PMID: 32109457     DOI: 10.1016/j.ejphar.2020.173031

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer.

Authors:  Keisuke Okuno; Rachana Garg; Yate-Ching Yuan; Masanori Tokunaga; Yusuke Kinugasa; Ajay Goel
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

2.  Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer.

Authors:  Yingying Kou; Bending Tong; Weiqing Wu; Xiangqing Liao; Min Zhao
Journal:  Front Pharmacol       Date:  2020-12-09       Impact factor: 5.810

3.  Zuo Jin Wan Reverses the Resistance of Colorectal Cancer to Oxaliplatin by Regulating the MALAT1/miR-200s/JNK Signaling Pathway.

Authors:  Zhenzhen Wei; Jing Zhou; Hao Yu; Yunzhou Pu; Yuelei Cheng; Yi Zhang; Qing Ji; Huirong Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2022-10-07       Impact factor: 2.650

4.  Synergistic Effect of Tangeretin and Atorvastatin for Colon Cancer Combination Therapy: Targeted Delivery of These Dual Drugs Using RGD Peptide Decorated Nanocarriers.

Authors:  He Bao; Nanbo Zheng; Zhuanting Li; Yuan Zhi
Journal:  Drug Des Devel Ther       Date:  2020-07-29       Impact factor: 4.162

Review 5.  Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers.

Authors:  Luying He; Zhangfeng Zhong; Man Chen; Qilian Liang; Yitao Wang; Wen Tan
Journal:  Front Pharmacol       Date:  2022-01-03       Impact factor: 5.988

6.  The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway.

Authors:  Liuyang Ren; Ying Lou; Mingyu Sun
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.